TG Therapeutics Inc (TGTX)

Debt-to-capital ratio

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	244,158	102,537	101,326	100,118	98,908	97,700	96,503	71,135	71,135	68,947	67,249	66,788	—	—	—	7,716	15,074	22,233	29,201	28,970
Total stockholders’ equity	US$ in thousands	192,157	177,568	160,109	160,502	164,769	40,453	27,433	58,587	100,481	129,035	170,386	237,153	311,517	383,130	445,285	519,350	170,658	194,227	-1,353	38,615
Debt-to-capital ratio		0.56	0.37	0.39	0.38	0.38	0.71	0.78	0.55	0.41	0.35	0.28	0.22	0.00	0.00	0.00	0.01	0.08	0.10	1.05	0.43

September 30, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $244,158K ÷ ($244,158K + $192,157K)
= 0.56

The debt-to-capital ratio of TG Therapeutics Inc has shown fluctuations over the past few quarters. As of September 30, 2024, the ratio stood at 0.56, indicating that 56% of the company's capital structure was financed through debt. This represents an increase from the previous quarter, where the ratio was 0.37.

Looking back over the last few years, the company experienced a significant spike in its debt-to-capital ratio in the first quarter of 2023, reaching 0.78, before gradually declining to more manageable levels. The ratio hit its lowest point in the first quarter of 2022 at 0.22, before rising again.

It is worth noting that the company had no debt as of December 31, 2021, and subsequently introduced debt into its capital structure. This indicates a shift in the company's financing strategy.

Overall, the trend in the debt-to-capital ratio suggests that the company has been actively managing its capital structure, with fluctuations reflecting changes in the level of debt relative to capital over time. Investors and stakeholders may monitor this ratio to assess the company's leverage position and risk profile.